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Abstract
Background: Numerous literary data indicate that dynorphin A (DYN-A) has a significant impact on cerebral circulation,
especially under pathophysiological conditions, but its potential direct influence on the tone of cerebral vessels is obscure.
The aim of the present study was threefold: 1) to clarify if DYN-A is present in cerebral vessels, 2) to determine if it exerts any
direct effect on cerebrovascular tone, and if so, 3) to analyze the role of k-opiate receptors in mediating the effect.
Methodology/Principal Findings: Immunohistochemical analysis revealed the expression of DYN-A in perivascular nerves of
rat pial arteries as well as in both rat and human intraparenchymal vessels of the cerebral cortex. In isolated rat basilar and
middle cerebral arteries (BAs and MCAs) DYN-A (1–13) and DYN-A (1–17) but not DYN-A (1–8) or dynorphin B (DYN-B)
induced strong vasoconstriction in micromolar concentrations. The maximal effects, compared to a reference contraction
induced by 124 mM K
+, were 11566% and 104610% in BAs and 11363% and 12569% in MCAs for 10 mM of DYN-A (1–13)
and DYN-A (1–17), respectively. The vasoconstrictor effects of DYN-A (1–13) could be inhibited but not abolished by both
the k-opiate receptor antagonist nor-Binaltorphimine dihydrochloride (NORBI) and blockade of Gi/o-protein mediated
signaling by pertussis toxin. Finally, des-Tyr
1 DYN-A (2–13), which reportedly fails to activate k-opiate receptors, induced
vasoconstriction of 45611% in BAs and 5065% in MCAs at 10 mM, which effects were resistant to NORBI.
Conclusion/Significance: DYN-A is present in rat and human cerebral perivascular nerves and induces sustained contraction
of rat cerebral arteries. This vasoconstrictor effect is only partly mediated by k-opiate receptors and heterotrimeric Gi/o-
proteins. To our knowledge our present findings are the first to indicate that DYN-A has a direct cerebral vasoconstrictor
effect and that a dynorphin-induced vascular action may be, at least in part, independent of k-opiate receptors.
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Introduction
Although the perivascular nerves of brain vessels were already
recognized by Thomas Willis in the 17
th century [1], their role in
the regulation of cerebral circulation is still poorly understood
[2,3]. Since the development of the metabolic homeostasis concept
by Roy and Sherrington in 1890 [4], cerebrovascular research has
been focused primarily on paracrine mediators of cerebral blood
flow (CBF) regulation. However, recent advances in functional
neuroimaging techniques have called our attention to vascular
reactions which cannot be completely explained by this paradigm
[5,6]. Most notably, it has been clearly shown that changes in CBF
precede the release of metabolic and endothelium-derived
mediators during neuronal activation. Furthermore, in some
disorders of the cerebral circulation, like vascular migraine
headache, vasomotion and vasospasm following subarachnoid
hemorrhage or traumatic brain injury, CBF is completely
uncoupled from the metabolic demands of neurons. Therefore,
the concept of neural regulation and the ‘‘functional neurovascular
unit’’ has been recently reappraised [2,6].
Cerebral vessels receive dense innervation either via the
peripheral nervous system or directly from the central nervous
system (CNS) [2,3]. The former is often called ‘‘extrinsic
innervation’’ and includes sympathetic, parasympathetic and
sensory nerve fibers. In contrast, ‘‘intrinsic innervation’’ of the
cerebral vessels includes local interneurons and nerve fibers
originating from the locus coeruleus, raphe nuclei, basal forebrain,
thalamus and nucleus fastigii of the cerebellum. The most
important neurotransmitters of cerebral perivascular nerves are
norepinephrine, acetylcholine, nitric oxide, serotonin, glutamate,
c-aminobutyric acid and various neuropeptides including opioid
peptides [7,8]. Enkephalins have been identified in cerebral
perivascular nerve fibers of humans, pigs, cats, rabbits, pigeons
and rats [9–13]. In swine middle cerebral arteries (MCAs) Met-
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37798and Leu-enkephalin immunoreactivity was localized in large dense
core vesicles of noradrenergic perivascular nerves [10,11].
Interestingly, sympathoadrenal stimulation by acute cerebral
ischemia (Cushing response) induced a 70% decrease of the
MCA enkephalin content, an effect that was absent after the
depletion of catecholamines, indicating an interaction between the
sympathetic and enkephalinergic regulation of the cerebral
circulation.
Beside of enkephalins other endogenous opioid peptides, like b-
endorphin and dynorphins, have also been implicated in
cerebrovascular regulation, but their expression in the cerebral
vasculature is less documented [8,14]. In 1986 Moskowitz and
colleagues described the presence of dynorphin B (DYN-B) in
guinea-pig cerebral perivascular nerves [15], an observation that
has been confirmed subsequently by the same authors in rats [16]
and later by others in monkeys [17]. Furthermore, measurable
levels of DYN-B were detected in isolated human, canine, bovine
and feline cerebral vessels [16]. However, the potential role of
DYN-B in the regulation of cerebral circulation remained obscure,
since it failed to induce any effect in cerebral arteries isolated from
dogs [15] or rats [17]. In the present study we aimed to investigate
the cerebrovascular expression and potential vasoactive effects of
the other member of the dynorphin family, dynorphin A (DYN-A).
Functional experiments were performed in isolated basilar arteries
(BAs) and MCAs, representing two different regions of pial vessels,
because with this approach the direct vascular effects of DYN-A
could be determined. Since we found that DYN-A is present in
perivascular nerves of cerebral arteries and induces sustained
vasoconstriction, we further investigated the roles of k-opiate
receptors and Gi/o proteins in mediating this vasoactive effect.
Methods
Ethics Statement
The experiments were performed according to the guidelines of
the Hungarian Law of Animal Protection (243/1988), and all
procedures were approved by the Semmelweis University Com-
mittee on the Ethical Use of Experimental Animals (590/99 Rh).
Immonohistochemistry
Adult male Wistar rats (350–450 g bw.) were anesthetized with
80 mg/kg Ketamine (CP Pharma, Burgdorf, Germany) and
160 mg/kg Primazin (Alfason, Woerden, Netherlands) and
perfused transcardially with 0.9% saline followed by 300 ml of
4% paraformaldehyde, pH 7.4. The brains were removed and
post-fixed overnight in a fresh solution at 4uC.
Pial vessels (BA, MCAs and their main branches) were
immunostained as whole-mount preparations. After washing in
0.1 M phosphate buffer (PB) pH 7.4, the specimens were treated
with 0.5% Triton X-100 and 10% normal goat serum for 1 h each
at room temperature. The endogenous peroxidase activity was
blocked by a 15-min incubation in 3% H2O2 (Reanal, Budapest,
Hungary). In order to visualize perivascular nerve fibers the vessels
were incubated in mouse anti-synaptophysin antibody (1:1000;
Millipore, Budapest, Hungary) for 36 h at 4uC. Alexa Fluor 633
labeled anti-mouse secondary antibody (1:500, made in goat,
Invitrogen, Carlsbad, CA, USA) was used for 1 h at room
temperature. Immunohistochemistry of DYN-A was performed as
described below for brain sections.
Expression analysis of cortical intraparenchymal vessels were
performed in 50 mm thick horizontal sections of rat brains
prepared and post-fixed as described above, and cryoprotected
with 20% sucrose for 24 h at 4uC. Small blocks of human brain
(from Human Brain Tissue Bank, Semmelweis University,
Budapest) were cut from the temporal cortex (post mortem delay:
10 h), fixed in 4% paraformaldehyde for 48 h at pH 7.4, and
cryoprotected with 20% sucrose for 24 h at 4uC. Serial, 50 mm
thick coronal sections were cut on a frigomobile (Frigomobil,
Reichert-Jung, Vienna, Austria).
After washing in 0.1 M PB pH 7.4, sections were treated with
0.5% Triton X-100 and 10% normal goat serum for 1 h each at
room temperature. The endogenous peroxidase activity was
blocked by a 15-min incubation in 3% H2O2 (Reanal, Budapest,
Hungary). Sections were next incubated in anti-DYN-A (1–13)
antibody (1:2500, made in rabbit, Peninsula Laboratories Inc., San
Carlos, CA, USA) for 36 h at 4uC, in biotinylated anti-rabbit
secondary antibody (1:1000, made in goat, Vector Laboratories,
Burlingame, CA, USA) for 1 h at room temperature and in
avidin–biotin–horseradish peroxidase complex (1:500, Vectastain
ABC Elite kit, Vector Laboratories, Burlingame, CA, USA) for 1 h
at room temperature. The sections were then incubated in FITC-
tyramide (1:10,000) and 0.015% H2O2 in 0.05 M Tris buffer at
pH 8.2 for 10 min. Between the incubation steps, the sections
were rinsed three times for 10 min in PB. Western blot analysis of
the specificity of the primary antibody revealed similar affinities to
DYN-A (1–13) and DYN-A (1–17), but no cross-reaction with
DYN-A (1–8) or DYN-B.
Sections were mounted on Superfrost slides, and the slices were
coverslipped with Aqua-Poli Mount (Polysciences, Inc., Warring-
ton, USA). Confocal images of slides and whole mount prepara-
tions were acquired with a Zeiss LSM 510 META (Carl Zeiss,
Jena, Germany) confocal laser scanning microscope using a 20X
DIC (Plan Apochromat, NA=0.80) or 63X DIC (Plan Apoc-
hromat oil immersion, NA=1.4) objective and processed by LSM
AIM 4.0 software.
Myograph experiments
Adult male Wistar rats (350–450 g bw.) were exsanguinated
rapidly under deep ether anesthesia and 2–3 mm long ring
segments of the BAs and MCAs were prepared as described
previously [18,19]. Special care was taken to preserve the
endothelium during preparation. The segments were transferred
to 6-mL organ baths of a conventional myograph system (610 M,
Danish Myo Technology A/S, Aarhus, Denmark) filled with a
modified Krebs solution of the following composition (mmol/L):
NaCl 119, KCl 4.7, KH2PO4 1.2, CaCl2?2H2O 2.5,
MgSO4?7H2O 1.2, NaHCO3 20, EDTA 0.03 and glucose 10.
The bath solution was bubbled continuously with carbogen (95%
O2/5% CO2) in order to maintain a pH of 7.4. The vessel
segments were mounted on two L-shaped tungsten wires (75 and
50 mm in diameter for BA and MCA, respectively): one wire was
fixed to the wall of the bath, and the other was fixed to a force
transducer. Isometric vascular tensions were recorded by the
MP100 data acquisition system and analyzed with the AcqKnow-
ledge 3.8.2 software of BIOPAC Systems (Goleta, CA, USA).
The vessels were allowed a 45-minute equilibration period,
during which the resting tension was adjusted to 3.5–4.5 mN (BA)
or 1.5–2.5 mN (MCA), and the bath solution was warmed to 37uC
with repeated washing in every 15 minutes. Thereafter, each
segment was exposed to 124 mmol/L K
+ Krebs solution to elicit a
reference contraction. After a 30-min resting period, the effects of
dynorphins were tested either on the resting tension or after
precontraction with 10 mM serotonin (BA) or 100 mM UTP
(MCA). (Since the results of the first experiments clearly showed
that none of the tested dynorphins induce any relaxation in a
precontracted vessel, in all further experiments they were applied
on the resting tension in order to study their contractile effects.) At
the end of the experiments, the functional integrity of the
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10 mM bradykinin (MCA) or acetylcholine (BA) after induction of
precontraction as described above. According to results of previous
studies [18,20] segments that did not exhibit at least 40% (BA) or
20% (MCA) relaxation of the precontraction were considered to
have damaged endothelium and were excluded from the study.
Some segments were pretreated with pertussis toxin (PTX)
before mounting on the myograph in order to evaluate the role of
heterotrimeric Gi/o-proteins in mediating the vascular effects of
DYN-A. These vessels were incubated with 3 mg/ml PTX
overnight at 37uC and vehicle-treated vessels undergoing the
same procedure served as controls.
Changes in vascular tension are expressed as percentage of the
reference contraction induced by 124 mmol/L K
+ Krebs solution
and presented as mean6SEM. Statistical analysis was performed
using one-way ANOVA followed by Tukey’s post hoc test or
Student’s t-test, as appropriate; n represents the number of
experiments. A P value of less than 0.05 was considered to be
statistically significant.
DYN-A (1–13) was from Merck KGaA (Darmstadt, Germany),
DYN-A (2–13) was synthesized by CASLO Laboratory ApS
(Lyngby, Denmark). Other dynorphins used in this study were
from Bachem AG (Bubendorf, Switzerland). Dynorphins were
freshly dissolved on the day of the experiment and were kept on ice
until administration. PTX, bradykinin and nor-Binaltorphimine
dihydrochloride (NORBI) were from Tocris Bioscience (Bristol,
UK). All other chemicals were obtained from Sigma-Aldrich (St.
Louis, MO, USA).
Results
Rat pial arteries, including the BA and MCA, ubiquitously
showed DYN-A immunoreactivity in the adventitia of the vessels.
DYN-A was co-localized with synaptophysin, indicating its
presence in presynaptic vesicles (Figure 1). DYN-A immunoreac-
tive perivascular nerves followed the vessels after their entry into
the brain parenchyma (Figure 2A and 2B) and surrounded
approximately 50% of the intraparenchymal arteries of the
cerebral cortex (Figure 2C and 2D). Three-dimensional recon-
struction of brain slices clearly showed the network of DYN-A
positive nerves around the vessels (Supplementary Video S1).
Interestingly, human cerebrocortical arteries showed a similar
pattern of DYN-A expression (Figure 2E and 2F). Furthermore,
dynorphinergic nerves were also observed around rat cerebrocor-
tical arterioles (Figure 3), which play a major role in the regulation
of the local tissue blood flow. In longitudinal sections of
intraparenchymal arterioles it was obvious that the density of
DYN-A positive fibers varies significantly from segment to
segment of the vessel (Figure 3A and 3B) but none of the
cerebrocortical layers appeared to show higher or lower perivas-
cular DYN-A expression.
The potential vasoactive effects of naturally occurring dynor-
phins [DYN-A (1–8), (1–13), (1–17) and DYN-B] were determined
both on the resting tension and after precontraction of rat cerebral
arteries. No relaxant effect of any of the tested peptides was
observed, although the functional integrity of the endothelium and
the ability of the vessels to relax were verified by the normal
reactivity of the BAs and MCAs to acetylcholine and bradykinin,
respectively (data not shown). In contrast, when applied on the
resting tension, both DYN-A (1–13) and DYN-A (1–17) but not
DYN-A (1–8) induced very strong vasoconstriction in micromolar
concentrations (Figure 4). The vasoconstrictor effects of 10 mM
DYN-A (1–13) and DYN-A (1–17) were stronger than the
reference contraction induced by 124 mM K
+, and did not
decline within 10 minutes until the baths were washed with fresh
Figure 1. Dynorphin A (DYN-A) is present in perivascular nerves of the rat basilar artery. Localization of DYN-A in perivascular nerve
fibers of rat basilar artery by immunofluorescent confocal microscopy. Anti-synaptophysin staining (red fluorescence) indicates the synaptic vesicles
of perivascular nerves on the surface of the basilar artery (A). DYN-A (1–13) (green fluorescence) is abundantly found in the adventitia (B) and co-
localized with synaptophysin (C). Bar=100 mm.
doi:10.1371/journal.pone.0037798.g001
Figure 2. Dynorphin A (DYN-A) is present in perivascular
nerves of rat and human intraparenchymal arteries. Oblique
sections of rat (A and B) as well as longitudinal sections of rat (C and D)
and human (E and F) cerebral arteries are shown. Merged images of
DYN-A (1–13) immunoreactivity (green fluorescence) and transmitted-
light (grayscale) indicate the perivascular localization of DYN-A. Broken
line shows the surface of the brain on panels A and B, asterisks indicate
red blood cell clots in the lumen of the artery on panel F. Bar=50 mm
on each panel.
doi:10.1371/journal.pone.0037798.g002
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(Figure 4).
The k-opiate receptor antagonist NORBI was able to reduce
the vasoconstrictor effect of DYN-A (1–13) both in BAs (Figure 5A)
and MCAs (Figure 5B), whereas its vehicle (saline) was without any
effect (Figures 5C and 5D). Furthermore, inhibition of Gi/o-
mediated signaling with PTX also inhibited the vasoconstrictor
effects of DYN-A (1–13) (Figures 6A and 6B), indicating the
involvement of Gi/o-coupled k-opiate receptors in the mediation of
the effect. However, neither NORBI nor PTX was able to abolish
the DYN-A-induced cerebrovascular constriction completely,
indicating that a k-opiate receptor-independent mechanism may
also contribute to its mediation. In accordance with this
assumption, DYN-A (2–13), which is inactive at opiate receptors,
was also able to induce weaker but significant vasoconstriction in
both BAs (Figure 7A) and MCAs (Figure 7B), and these effects
were resistant to NORBI (Figure 7A and 7B).
Discussion
Various and in many cases conflicting data have been published
on the roles of opioid peptides, opiates and their receptors in
cerebral circulation. In a review published in 1996, based on the
literature available at the time, we drew the conclusion that the
endogenous opioid system represents a latent regulatory mecha-
nism, which is of limited importance under resting conditions but
may significantly influence cerebral circulation in pathophysiolog-
ical states [8]. Although numerous papers have been published on
this field in the last 16 years as well, the effects of endogenous
opiates on cerebrovascular functions are still obscure. In the
present study we show that DYN-A is present in cerebral
perivascular nerves and induces strong vasoconstriction, which is
mediated by both k-opiate receptor-dependent and -independent
mechanisms.
There are numerous controversies in the literature regarding
the role of dynorphins and k-opiate receptors in cerebral
circulation [8]. In the early studies of Altura et al. some synthetic
agonists of k-opiate receptors induced vasorelaxation, whereas
others brought about constriction in canine cerebral arteries
[21,22]. However, the mediation of the vasoconstrictor effect was
attributed to s-receptors. In 1986 Sa ´ndor et al. demonstrated that
intracerebroventricular (ICV) administration of DYN-A (1–13)
results in a reduction of the hypothalamic blood flow without
changing global CBF or cerebral blood volume in rats [3].
However, the question whether DYN-A had a direct vasocon-
strictor effect, or the reduction of the blood flow was secondary to
changes in neurovascular regulation and/or neuronal metabolic
activity remained open.
The role of dynorphins in cerebrovascular regulation has been
studied extensively by Armstead and co-workers in newborn and
Figure 3. Dynorphin A (DYN-A) is present in perivascular
nerves of the rat intraparenchymal arterioles. Several arterioles
(indicated by arrows) are present in tile scan images (A and B) of a
9006900 mm large cortical area. C and D panels show the selected
region of the upper panels. Overlay of DYN-A (1–13) immunoreactivity
(green fluorescence) and transmitted light images (grayscale) on panels
B and D indicate the perivascular expression of DYN-A. Broken line
shows the surface of the brain. Bar indicates 200 mm on upper panels
and 50 mm on lower panels.
doi:10.1371/journal.pone.0037798.g003
Figure 4. Dynorphin A (DYN-A) (1–13) and (1–17) induce strong contraction of rat cerebral arteries. Effects of cumulative concentrations
of DYN-A (1–8), (1–13), (1–17) and Dynorphin B (DYN-B) on the resting tension of rat basilar (A) and middle cerebral (B) arteries. DYN-A (1–13) and
DYN-A (1–17) induce strong, dose-dependent vasoconstriction in both vessels, whereas DYN-A (1–8) and DYN-B have no significant effect. Values are
expressed as mean6SEM percentage of the reference contraction induced by 124 mmol/L K
+ Krebs solution, n=6–37. *P,0.05, **P,0.01,
***P,0.001 vs. DYN-A (1–8);
##P,0.01,
###P,0.001 vs. DYN-B.
doi:10.1371/journal.pone.0037798.g004
Cerebrovascular Effects of Dynorphin A
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13) induced vasodilation in pial arteries and arterioles, which was
reversed to vasoconstriction during hemorrhagic hypotension or
sustained hypoxia as well as after fluid percussion brain injury [23–
29]. Since DYN-A failed to influence the cerebral metabolic rate
of glucose [26], an indirect effect on pial vessels through
modulation of the neuronal metabolic activity could be excluded.
It was also shown that the vasodilator effect of DYN-A is mediated
by NO and probably by the activation of ATP- and Ca
++-sensitive
K
+-channels [30–32]. Interestingly, DYN-A increased the vaso-
pressin concentration in the cerebrospinal fluid, an effect that
appeared to be responsible for the pial arterial vasoconstriction
induced by DYN-A during hemorrhagic hypotension and
sustained hypoxia as well as after traumatic brain injury
[27,29,33,34].
In our present study none of the naturally occurring dynorphins
induced any vasorelaxant effect in isolated cerebral vessels of adult
rats, in spite of the facts that rat cerebrovascular endothelial cells
do express k-opiate receptors [35], and the functional integrity of
the endothelium has been verified in our experiments. Although
this discrepancy between our results and those of Armstead et al.
could be explained as age- or species-related differences in
cerebrovascular reactivity, we suggest that it is due to the different
experimental approaches. Since in newborn pigs DYN-A-induced
pial vasorelaxation was accompanied by an almost three-fold
increase in cyclic GMP concentration in the cerebrospinal fluid
[30], it is likely that it was mediated by neuronal release of NO. In
contrast, in our in vitro experiments only the direct vascular effects
of DYN-A were observed. However, the cellular mechanism of the
dynorphin action cannot be identified exactly from our results
either. It is unlikely that perivascular nerves would mediate the
vasoconstriction, since even if they expressed k-opiate receptors
one would expect a decrease of neurotransmitter release upon
their activation by DYN-A. On the other hand, the endothelium
may be involved in the vasoconstrictor effect of DYN-A, since it
express k-opiate receptors [35], which were shown to mediate
endothelin-release [36]. Finally, DYN-A may directly stimulate
smooth muscle contraction as it has been demonstrated in the
gastrointestinal system [36–41].
Figure 5. Dynorphin A (DYN-A) induced cerebral vasoconstriction is partly mediated by k-opiate receptors. Effect of the k-opiate
receptor antagonist nor-Binaltorphimine dihydrochloride (NORBI, 50 mM) on the responsiveness of rat basilar (A) and middle cerebral (B) arteries to
DYN-A (1–13). NORBI was able to reduce the vasoconstrictor effect of DYN-A in both vessels, whereas its vehicle (saline) was without any effect (C and
D). Values are expressed as mean6SEM percentage of the reference contraction induced by 124 mmol/L K
+ Krebs solution, n=8–10. Asterisks
indicate significant (**P,0.01, ***P,0.001) differences between values before and after NORBI treatment.
doi:10.1371/journal.pone.0037798.g005
Cerebrovascular Effects of Dynorphin A
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37798Endogenous opioid peptides have been implicated as patho-
physiological factors in the development of traumatic and ischemic
lesions of the CNS [42]. Elevated DYN-A levels together with
upregulation of k-opiate receptors were reported at regions of
spinal cord injury [43–45], and k-opiate receptor antagonists were
able to prevent posttraumatic neurological deficits [46,47].
Furthermore, it has been demonstrated that (i) intrathecal infusion
of DYN-A by itself is able to induce energy depletion, edema
formation and neurologic motor dysfunction in the spinal cord
[48–51], and (ii) both ICV and systemic administration of DYN-A
and synthetic k-opiate agonists prior to induction of brain injury
worsens the posttraumatic neurological outcome [52]. In our
experiments vertebral arteries, similarly to BAs and MCAs, also
developed contraction in response to DYN-A (data not shown), an
observation that may elucidate the mechanism of dynorphin-
related traumatic spinal cord injury. Consistently with this
hypothesis, DYN-A (1–8), which was without any vasoconstrictor
effect in our present study, failed to reproduce the detrimental
consequences of intrathecal infusion of DYN-A (1–13) or DYN-A
(1–17) [48–50].
An important finding of the present study is that the
cerebrovascular effect of DYN-A is only partly mediated by k-
opiate receptors, and DYN-A (2–13), which lacks the amino
terminal tyrosine and therefore the affinity to opiate receptors, can
also induce cerebral vasoconstriction. Since aminopeptidase-
mediated conversion is a common route of dynorphin-metabolism,
Figure 6. Dynorphin A (DYN-A) induced cerebral vasoconstriction is partly mediated by heterotrimeric Gi/o-proteins. Effect of the
inhibition of Gi/o-signaling with pertussis toxin (PTX, applied as described in ‘‘Methods’’) on the responsiveness of rat basilar (A) and middle cerebral
(B) arteries to DYN-A (1–13). In control vessels the slightly weaker reactions to DYN-A (as compared to the previous figures) were probably the
consequence of overnight incubation in the Krebs solution containing the vehicle of PTX. PTX inhibited the vasoconstrictor effects of DYN-A. Values
are expressed as mean6SEM percentage of the reference contraction induced by 124 mmol/L K
+ Krebs solution, n=6–8. Asterisks indicate significant
(*P,0.05, **P,0.01) differences between PTX-treated and vehicle-treated control vessels.
doi:10.1371/journal.pone.0037798.g006
Figure 7. Dynorphin A (DYN-A) (2–13) induces contraction of rat cerebral arteries independently of k-opiate receptors. Effects of
DYN-A (2–13) on the tone of rat basilar (A) and middle cerebral (B) arteries before and after treatment with the k-opiate receptor antagonist nor-
Binaltorphimine dihydrochloride (NORBI, 50 mM). DYN-A (2–13), which is reportedly inactive at opiate receptors, evoked weaker [in comparison to
DYN-A (1–13) shown in previous figures] but significant contractions in both vessels, and these effects were resistant to NORBI. Values are expressed
as mean6SEM percentage of the reference contraction induced by 124 mmol/L K
+ Krebs solution, n=6–9.
doi:10.1371/journal.pone.0037798.g007
Cerebrovascular Effects of Dynorphin A
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present in vivo [52,53]. For instance, DYN-A (2–13) was reported
to be one of the main DYN-A (1–13) metabolite both in the
human plasma and cerebrospinal fluid [54,55]. Therefore, the
cerebral vasoconstriction induced by DYN-A (1–13) may persist
after the degradation of the peptide.
It has been shown in neuronal cells and membrane preparations
that DYN-A may bind to several non-opioid receptors including
muscarinic receptors [56], N-methyl-D-aspartate (NMDA) recep-
tors [57,58], the orphanin receptor [59], melanocortin receptors
[60], neuropeptide Y and peptide YY receptors [61], the
membrane glucocorticoid receptor [62] and bradykinin-receptors
[63]. Further studies will be required to clarify whether it is any of
these receptors or other mechanisms that mediate the non-k-
opiate receptor related vasoconstrictor effect of DYN-A. It is
noteworthy, however, that DYN-A induced CNS injury is also
partly independent of k-opiate receptors [64–66], a similarity that
underlines the potential role of the vasoconstrictor effect of DYN-
A in the development of the posttraumatic neurological dysfunc-
tion.
In conclusion, the present study shows that DYN-A (1–13) and/
or DYN-A (1–17) are present in cerebral perivascular nerves and
both are able to induce sustained contraction of cerebral arteries,
whereas DYN-A (1–8) and DYN-B have no such effect. The DYN-
A-induced vasoconstriction is only partly mediated by k-opiate
receptors and heterotrimeric Gi/o-proteins. To our knowledge, our
present findings are the first to indicate that a dynorphin-induced
vascular effect may be, at least in part, independent of k-opiate
receptors.
Supporting Information
Video S1 Perivascular localization of Dynorphin A
(DYN-A) in a rat cerebral artery. Three-dimensional
reconstruction of a 50 mm thick brain slice containing an oblique
section of a cerebral artery. Purple color indicates the autofluo-
rescence of the arterial media layer, whereas green fluorescence
corresponds to DYN-A immunostaining. DYN-A positive nerve
fibers are shown to closely entwine the vascular smooth muscle.
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